Real-time AI-generated research reports the moment unusual volume is detected in penny stocks and microcap equities.
No contracts. Cancel anytime. 7-day free trial included.
Every Microcap Catalyst report is delivered to subscribers the moment it is generated. The identical report is published publicly exactly 7 days later. By the time the crowd sees it, you have had a full week to act on the information. This is the core value proposition of the product — and it is written into every alert we send.
The Pipeline
Every 15 minutes during market hours, the scanner screens the full microcap universe (sub-$300M market cap, $0.50–$10 price range) for volume spikes exceeding 300% of the 20-day average.
Within minutes, the AI cross-references news feeds, SEC filings, press releases, and social signals to identify what is driving the volume.
A complete VETTA-style research report is generated: catalyst summary, technical setup, risk factors, SEC filing cross-reference, and investment thesis.
You receive an email alert with the full report the moment it is published — 7 days before the public sees it.
One week after subscriber delivery, the report is published publicly. By then, the early-access window has closed.
What You Get
Microcap Catalyst is a standalone product. It does not require a Volatility Anomaly Pro subscription. It is priced to be accessible to any active trader who wants an edge in the microcap space.
Pricing
Standalone subscription
Cancel anytime. No contracts.
Secure checkout via Stripe. 7-day free trial, then $19/month.
Already a VA Pro member? Microcap Catalyst is a separate add-on at $19/month.
Public Archive
These reports were delivered to subscribers 7 days ago. Subscribe to receive the next one the moment it is generated.
Prelude Therapeutics 445% volume spike follows 47% response rate in Phase 2 HDAC inhibitor data. SMARCB1-deficient tumor indication creates rare oncology opportunity at 1:1 market cap to peak revenue.
AudioEye 521% volume spike follows DOJ ADA web accessibility rule finalization. New mandate creates $192M TAM expansion for AEYE's compliance SaaS platform.
Coda Octopus Group 394% volume spike follows $4.2M Navy contract. The underwater drone company trades at 6x earnings with real-time 3D sonar technology moat.
MicroVision 612% volume spike follows favorable patent ruling in LiDAR infringement case. MVIS IV at 91st percentile creates iron condor opportunity with defined Q3 trial timeline.
FDA Priority Review for pediatric TPOXX triggers 487% volume spike. SIGA holds the only FDA-approved smallpox antiviral — a biodefense monopoly with government contract backing.
Subscriber reports are currently in their 7-day early access window. Subscribe to receive the full archive including all reports not yet released to the public.
FAQ
The crowd will see this report in 7 days. Subscribers see it now. For $19/month, that edge is yours on every single catalyst we detect.
7-day free trial. Cancel anytime. No contracts.
The Microcap Catalyst Scanner is a real-time automated system for identifying unusual volume activity in penny stocks, small-cap equities, and microcap stocks priced between $0.50 and $10.00 with market capitalizations below $300 million. Unlike traditional stock screeners that display raw volume data, this system identifies the catalyst behind each volume spike and delivers a complete AI-generated research report within minutes of detection.
Volume anomalies are defined as intraday volume exceeding 300% of the 20-day average. Each qualifying event triggers an AI pipeline that cross-references news feeds, SEC filings, press releases, and social signals to produce a structured VETTA-style analysis covering catalyst identification, technical setup, risk factors, and investment thesis.
Subscribers receive every report immediately upon generation — 7 days before the same report is released to the public. This early access window is the core value proposition of the Microcap Catalyst product and is enforced programmatically on every report in the archive.
Risk Disclosure: Microcap and penny stocks involve significantly higher risk than large-cap equities, including illiquidity, price manipulation, limited public information, and extreme volatility. The Microcap Catalyst Scanner is an informational research tool, not investment advice. All reports are AI-generated and should not be relied upon as the sole basis for any investment decision. Past performance does not guarantee future results. Options trading involves substantial risk of loss and is not appropriate for all investors.